Clinical First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors. February 23, 2024Vol.50 No.08By Matthew Bin Han Ong